Evolus, Inc. (NASDAQ:EOLS) is Stonepine Capital Management LLC’s 2nd Largest Position

Stonepine Capital Management LLC cut its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 17.4% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,369,821 shares of the company’s stock after selling 287,790 shares during the period. Evolus comprises approximately 14.0% of Stonepine Capital Management LLC’s portfolio, making the stock its 2nd largest holding. Stonepine Capital Management LLC’s holdings in Evolus were worth $22,191,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. BNP Paribas Financial Markets increased its position in shares of Evolus by 99.5% during the third quarter. BNP Paribas Financial Markets now owns 62,748 shares of the company’s stock worth $1,017,000 after purchasing an additional 31,300 shares in the last quarter. FMR LLC lifted its stake in shares of Evolus by 67.8% in the third quarter. FMR LLC now owns 80,316 shares of the company’s stock valued at $1,301,000 after purchasing an additional 32,444 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Evolus during the 3rd quarter worth approximately $191,000. Charles Schwab Investment Management Inc. boosted its position in shares of Evolus by 173.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock worth $6,781,000 after buying an additional 265,635 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of Evolus during the 3rd quarter worth approximately $228,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Barclays raised their price target on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Evolus in a report on Thursday, November 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a research note on Monday, September 16th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Evolus in a research report on Friday, September 13th.

Insider Buying and Selling at Evolus

In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the transaction, the chief marketing officer now directly owns 82,375 shares in the company, valued at $1,305,643.75. This represents a 6.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. This represents a 2.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Evolus Stock Performance

Shares of EOLS traded up $0.48 on Wednesday, reaching $13.31. 60,634 shares of the stock traded hands, compared to its average volume of 592,533. The stock’s 50-day moving average price is $15.42 and its 200-day moving average price is $13.86. Evolus, Inc. has a 12 month low of $9.32 and a 12 month high of $17.82. The firm has a market cap of $842.79 million, a price-to-earnings ratio of -14.10 and a beta of 1.31. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.